EADV 2023 Insights


 

EADV 2023 Insights: Impact of Povorcitinib on DLQI and DLQI Subdomains in Patients with Hidradenitis Suppurativa: Results from a Randomized, Placebo-Controlled Phase 2 Study

120 views
October 16, 2023
Comments 0
Login to view comments. Click here to Login